Syndax Pharmaceuticals (SNDX) Return on Capital Employed (2016 - 2026)

Syndax Pharmaceuticals' Return on Capital Employed history runs 11 years deep, the most recent figure standing at 53.86% for Q1 2026.

• In Q1 2026, Return on Capital Employed rose 461.0% year-over-year to 53.86%; the TTM figure through Mar 2026 stood at 53.86% (up 461.0% YoY), while the FY2025 annual figure was 53.85%, up 624.0% from the prior year.
• Return on Capital Employed was 53.86% for Q1 2026 at Syndax Pharmaceuticals, up from 64.92% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 4.08% in Q1 2022 to a low of 81.94% in Q3 2024.
• Historically, Return on Capital Employed has averaged 46.71% across 5 years, with a median of 51.6% in 2023.
• The sharpest annual moves came in 2022 and 2023: Return on Capital Employed surged 3640 bps in 2022, then tumbled 4775 bps in 2023.
• A 5-year view of Return on Capital Employed shows it stood at 38.0% in 2022, then slumped by 35 bps to 51.33% in 2023, then slumped by 40 bps to 72.0% in 2024, then increased by 10 bps to 64.92% in 2025, then gained by 17 bps to 53.86% in 2026.
• The last three Return on Capital Employed figures came in at 53.86% (Q1 2026), 64.92% (Q4 2025), and 66.75% (Q3 2025), per Business Quant data.